Engineered trimeric ACE2 binds viral spike protein and locks it in"Three-up"conformation to potently inhibit SARS-CoV-2 infection

• 来源期刊: 细胞研究（英文版）
• 年，卷（期）: 2021,（1）
• 所属期刊栏目: LETTERS TO THE EDITOR
• 页码范围: 98-100
• 页数: 3页
• 语种: 英文

摘要

Dear Editor, Coronavirus disease 2019(COVID-19)caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)has resulted in a severe global pandemic.Following SARS-CoV,SARS-CoV-2 is yet another emergent beta-coronavirus threatening human health.1 However,seventeen years after the SARS pandemic,no targeted vaccines or therapeutics have been approved for SARS,while some of them might have held promise for treating COVID-19.Many neutralizing antibodies against SARS-CoV-2 are currently being developed.However,RNA viruses are known to have high mutation rates.Many SARS-CoV-2 mutations have already been identified such as D614G,2 and these resultant mutation strains might escape the effects of the current SARS-CoV-2 neutralizing antibodies.The appearance of COVID-19 after SARS indicates the likely emergence of other coronavirus pandemics in the future.Thus,therapeutics broadly effective against SARS-CoV-2 and mutants,even other SARS-CoV-2-related coronaviruses(SARSr-CoVs),are highly desirable.Both SARS-CoV-2 and SARS-CoV bind ACE2 for cell entry,suggesting a general use of ACE2 by SARS-CoV-2 mutants and future related coronaviruses.Therefore,proteins engineered based on wild-type ACE2 might exhibit the best broad neutralizing activity and avoid the mutational escape.